NCT06258291尚未招募不适用
A Multi-center Randomized Controlled First in Human Trial to Assess the Feasibility and Preliminary Safety Data of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill PatientS with Sepsis-induced ImmunOsuppREssion (RESTORE I)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- hemotune AG
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Biomarker for sepsis induced immunosuppression (monocytic HLA-DR = mHLA-DR)
研究概览
简要总结
The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.
详细描述
The treatment safety and the kinetics of specific biomarkers will be assessed to evaluate the selection of the treatment regimen. In a first step, 16 patients will be randomized 1:1 into two arms:
Treatment arm 1: One treatment of 2 hours per day for a maximum of five days or until ICU discharge or death or withdrawal of consent, whichever occurs first.
Control arm: Five consecutive days following the first mHLA-DR measurement post study randomization, or until ICU discharge or death or withdrawal of consent, whichever occurs first
And the end of this treatment phase, it will be decided whether the dosage regimen of HemoSystem REBOOT needs to be adapted and another eight patients have to be enrolled with 2 treatments per day, and a maximum of five treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Written informed consent according to national requirements.
- •Hospitalized in ICU or IMC at randomization.
- •Expected length of intensive care unit stay (from randomization) >48 hours.
- •Suspected or confirmed bacterial sepsis.
- •Septic shock diagnosis at any time during ICU/IMC stay according to Sepsis - 3 criteria definition:
- •an infection (suspected or confirmed);
- •persisting hypotension requiring any dose of vasopressors (norepinephrine, vasopressin) to maintain a systemic mean blood pressure > 65 mmHg despite adequate fluid resuscitation (minimum of 30 ml/kg crystalloids);
- •elevated lactate ≥ 2.0 mmol/L with suspected hypoperfusion.
- •Persistent immunosuppression defined as mHLA-DR expression levels < 5600 Ab/cell (Cyto-Chex tubes) in at least two consecutive measurements 20-72 hours apart.
- •Exclusion criteria:
- •Current ongoing chronic treatment using immunosuppressive biologicals or active lymphocyte therapy (e.g. endoxan, rituximab) or corticosteroid use at a dose > 10 mg/day equivalent of prednisone. However, acute treatment using a maximum dose of hydrocortisone of 200 mg/day for sepsis is allowed.
- •Patient with preexisting known severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS).
- •Active or planned extracorporeal membrane oxygenation treatment.
- •Active or planned other extracorporeal blood purification treatments with systems like CytoSorb®, ToraymyxinTM, Gambro Adsorba, etc.
- •Patients post solid-organ transplantation.
- •Known active malignancy (i.e. patients under active anti-malignant treatment).
- •Acute severe burn injury > 20% of the body surface area.
- •Contraindication to use the HemoSystem:
- •Sensitivity / allergy to HemoSystem components
- •Body weight < 50 kg
- •Platelets count < 20,000/µL
- •History of heparin-induced thrombocytopenia.
- •Females who are known to be pregnant or known to be breastfeeding (b-HCG testing performed in female patients aged < 55 years),
- •Moribund patient with life expectancy < 48h
- •Known history of bleeding disorders or severe coagulopathies (e.g., Hemophilia A, Hemophilia B, Idiopathic Thrombocytopenic Purpura, Von Willebrand Disease types I, II, and III)
排除标准
- 未提供
结局指标
主要结局
Biomarker for sepsis induced immunosuppression (monocytic HLA-DR = mHLA-DR)
时间窗: pre-procedure immune marker levels compared to post-treatment levels at least 24 hours after last treatment (on average estimated day 6 after treatment start)
Change in mHLA-DR levels during treatment compared to the standard of care arm alone
次要结局
- To assess the total number of organ support free days in intensive and intermediate care unit(until the end of the initial ICU admission (on average day 10 after initial ICU admission))
- To assess the technical success of in vivo target removal(immediately after last treatment)
- To determine all-cause mortality up to 90 days follow-up(through the end of the study (on average 90 days follow up))
- To assess vasopressor doses during intensive and intermediate care unit stay(until the end of the initial ICU admission (on average day 10 after initial ICU admission))
- To assess the use of antimicrobial medication(through the end of the study (on average 90 days follow up))
- Number of SADEs in treatment arm(through the end of the study (on average 90 days follow up))
- Need for organ support therapy (the number of days on organ support in the intensive care unit (index admission) defined by (1) invasive mechanical ventilation, (2) Intermittent or continuous renal replacement therapy, (3) any vasopressor support.(until the end of the initial ICU admission (on average day 10 after initial ICU admission))
- To assess the change of Sequential Organ Failure Assessment (SOFA) score (ranging from 0 =normal to 4=significantly impaired per category)(through the end of the study (on average 90 days follow up))
- To evaluate the change in the biomarker (for sepsis-induced immunosuppression) mHLA-DR concentration at various timepoints during ICU stay(at admission to ICU, on the day of first, 2nd, 3rd, 4th, and 5th treatment, and daily up to 72 hours after last treatment.)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant FormulaFluColdNCT06158659Heilongjiang Feihe Dairy Co. Ltd.240
Unknown
不适用
Improving the Accuracy of Referrals of Patients With Chest PainChest PainHeart AttackMyocardial InfarctionAcute Coronary SyndromeMyocardial IschemiaNCT04904107VieCuri Medical Centre852
已完成
不适用
Immunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFSPost-COVID ME/CFSME/CFSNCT05710770Charite University, Berlin, Germany66
已完成
不适用
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in OncologyTherapeutic Patient EducationImmune Checkpoint InhibitorsAdvanced Non-small Cell Lung CancerImmune-related Adverse EventHead and Neck CancerMelanomaRenal Cell CarcinomaNCT03948724Institut Cancerologie de l'Ouest412
招募中
2 期
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral BloodLocally Advanced Head and Neck Squamous Cell CarcinomaNCT06240689Second Affiliated Hospital, School of Medicine, Zhejiang University104